SR One Capital Management, LP

In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 12, 2025), SR One Capital Management, LP reported 12 stock positions worth $691.4 million. Its top holding was Arcellx (ACLX) at 27.9% of the portfolio, followed by Crispr Therapeutics (CRSP, 19.1%) and Zenas Biopharma (ZBIO, 15.8%). Compared with Q2 2025, it sold out of 1, added to 1 and reduced 1. The biggest buy was Crispr Therapeutics (CRSP, shares +94%) and the biggest sale an exit from Kala Bio (KALA).

Most Recent 13F
Q2 2026
Location
Redwood City, CA
CIK
0001910264
Portfolio Value
$691.4M (Q3 2025)
SEC Filing
0001193125-25-277769 ↗ filed Nov 12, 2025

Holdings Value

0$500.0M$1.0B$1.5B Q1 2024: $364.1M Q1 2024 Q2 2024: $319.4M Q2 2024 Q3 2024: $498.7M Q3 2024 Q4 2024: $410.1M Q4 2024 Q1 2025: $389.3M Q1 2025 Q2 2025: $461.4M Q2 2025 Q3 2025: $691.4M $691.4M Q3 2025 Q4 2025: $706.4M Q4 2025 Q1 2026: $915.4M Q1 2026 Q2 2026: $1.0B Q2 2026

Holdings 12 stocks · $691.4M
ACLX Arcellx Inc. 27.86% 2,346,630 $192.7M No change
CRSP Crispr Therapeutics AG 19.11% 2,038,763 $132.1M Add +94.4%
ZBIO Zenas Biopharma Inc. 15.77% 4,911,539 $109.0M No change
MLYS Mineralys Therapeutics Inc. 11.59% 2,113,933 $80.2M Reduce -32.4%
ORIC Oric Pharmaceuticals Inc. 7.84% 4,514,929 $54.2M No change
DSGN Design Therapeutics Inc. 7.11% 6,526,476 $49.1M No change
SPRY Ars Pharmaceuticals Inc. 5.83% 4,012,903 $40.3M No change
ORKA Oruka Therapeutics Inc. 1.20% 430,330 $8.3M No change
ALMS Alumis Inc. 1.13% 1,959,896 $7.8M No change
NKTX Nkarta Inc. 1.00% 3,333,333 $6.9M No change
OCS Oculis Holding AG 0.82% 322,500 $5.7M No change
ENGN Engene Holdings Inc. 0.74% 747,750 $5.1M No change

Portfolio Sells Q2 2025 → Q3 2025
KALA Kala Bio Inc. Sold out 0.00% −0.62
MLYS Mineralys Therapeutics Inc. Reduce -32.4% 11.59% +2.42

Portfolio Buys Q2 2025 → Q3 2025
CRSP Crispr Therapeutics AG Add +94.4% 19.11% +8.05

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 15$1.0BMANE, ZBIO, CRSP, AVLN, DSGN
Q1 2026 14$915.4MACLX, MANE, ZBIO, CRSP, DSGN
Q4 2025 13$706.4MZBIO, ACLX, CRSP, DSGN, MLYS
Q3 2025 12$691.4MACLX, CRSP, ZBIO, MLYS, ORIC
Q2 2025 13$461.4MACLX, SPRY, CRSP, ZBIO, ORIC
Q1 2025 12$389.3MACLX, SPRY, MLYS, ZBIO, CRSP
Q4 2024 11$410.1MACLX, SPRY, CRSP, DSGN, ZBIO
Q3 2024 11$498.7MACLX, ZBIO, SPRY, CRSP, DSGN
Q2 2024 9$319.4MACLX, CRSP, SPRY, ALMS, MLYS
Q1 2024 6$364.1MACLX, CRSP, SPRY, NKTX, DSGN